As mentioned above, these discrepancies between DTCs and the primary tumour are not confined to ERα-expression: Solomayer et al. compared the HER2 status of DTC and primary tumour in 137 cases [8] and found that DTCs were more likely to express HER2 than the primary tumour. The gene discussed is ERBB2; the disease is neoplasm.